Jane S. Ricciuti, RPh, MS


June 03, 2004

In This Article


The US Food and Drug Administration (FDA) approved 2 new labeling changes to include information on pediatric use -- Corlopam (fenoldopam mesylate) injection and Zemplar (paricalcitol) injection.

Ketek (telithromycin) tablets, a new ketolide class of anti-infectives, received FDA approval for the treatment of community-acquired pneumonia (CAP), acute bacterial exacerbation of chronic bronchitis (ABECB), and acute bacterial sinusitis (ABS).

This month's column reviews FDA new product approvals and labeling changes for:

Antihypertensive Agents

  • Corlopam (fenoldopam mesylate) Injection

Anti-infective Agents

  • Ketek (telithromycin) Tablets

Antipsychotic Agents

  • Abilify (aripiprazole) Tablets

  • Zyprexa (olanzapine) Injection


  • Apidra (insulin glulisine [rDNA origin]) Injection

Respiratory Agents

  • Advair Diskus (fluticasone propionate/salmeterol xinafoate) Inhalation

Urologic Agents

  • Proscar (finasteride) Tablets

Vitamin D

  • Zemplar (paricalcitol) Injection